BACKGROUND: The use of chromium-containing dietary supplements is widespread among patients with type 2 diabetes. Chromium's effects in patients at high risk for developing diabetes, especially those with metabolic syndrome, is unknown. The objective of this study was to determine the effects of chromium picolinate (CrPic) on glucose metabolism in patients with metabolic syndrome. METHOD: A double-blind, placebo-controlled, randomized trial was conducted at a U.S. academic medical center. Sixty three patients with National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III)-defined metabolic syndrome were included. The primary end point was a change in the insulin sensitivity index derived from a frequently sampled intravenous glucose tolerance test. Prespecified secondary end points included changes in other measurements of glucose metabolism, oxidative stress, fasting serum lipids, and high sensitivity C-reactive protein. RESULTS: After 16 weeks of CrPic treatment, there was no significant change in insulin sensitivity index between groups (P = 0.14). However, CrPic increased acute insulin response to glucose (P 0.02). CrPic had no significant effect on other measures of glucose metabolism, body weight, serum lipids, or measures of inflammation and oxidative stress. CONCLUSION: CrPic at 1000 microg/day does not improve key features of the metabolic syndrome in obese nondiabetic patients.
RCT Entities:
BACKGROUND: The use of chromium-containing dietary supplements is widespread among patients with type 2 diabetes. Chromium's effects in patients at high risk for developing diabetes, especially those with metabolic syndrome, is unknown. The objective of this study was to determine the effects of chromium picolinate (CrPic) on glucose metabolism in patients with metabolic syndrome. METHOD: A double-blind, placebo-controlled, randomized trial was conducted at a U.S. academic medical center. Sixty three patients with National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III)-defined metabolic syndrome were included. The primary end point was a change in the insulin sensitivity index derived from a frequently sampled intravenous glucose tolerance test. Prespecified secondary end points included changes in other measurements of glucose metabolism, oxidative stress, fasting serum lipids, and high sensitivity C-reactive protein. RESULTS: After 16 weeks of CrPic treatment, there was no significant change in insulin sensitivity index between groups (P = 0.14). However, CrPic increased acute insulin response to glucose (P 0.02). CrPic had no significant effect on other measures of glucose metabolism, body weight, serum lipids, or measures of inflammation and oxidative stress. CONCLUSION:CrPic at 1000 microg/day does not improve key features of the metabolic syndrome in obese nondiabeticpatients.
Authors: Anthony J G Hanley; Ralph D'Agostino; Lynne E Wagenknecht; Mohammed F Saad; Peter J Savage; Richard Bergman; Steven M Haffner Journal: Diabetes Date: 2002-04 Impact factor: 9.461
Authors: Ethan M Balk; Athina Tatsioni; Alice H Lichtenstein; Joseph Lau; Anastassios G Pittas Journal: Diabetes Care Date: 2007-05-22 Impact factor: 19.112
Authors: Ray C Boston; Darko Stefanovski; Peter J Moate; Anne E Sumner; Richard M Watanabe; Richard N Bergman Journal: Diabetes Technol Ther Date: 2003 Impact factor: 6.118
Authors: Mahmood S Mozaffari; Rafik Abdelsayed; Ibrahim Zakhary; Mohammed El-Salanty; Jun Yao Liu; Hereward Wimborne; Ahmed El-Marakby Journal: J Oral Pathol Med Date: 2010-10-25 Impact factor: 4.253
Authors: Seth A Stein; Margaret Mc Nurlan; Brett T Phillips; Catherine Messina; Dennis Mynarcik; Marie Gelato Journal: J AIDS Clin Res Date: 2013-09-07
Authors: Betty J Herring; Amanda L Logsdon; Jarrett E Lockard; Brittany M Miller; Hanna Kim; Eric A Calderon; John B Vincent; Melissa M Bailey Journal: Biol Trace Elem Res Date: 2012-12-29 Impact factor: 3.738
Authors: Karla V G Lima; Raquel P A Lima; Maria C R Gonçalves; Joel Faintuch; Liana C S L Morais; Luiza S R Asciutti; Maria J C Costa Journal: Obes Surg Date: 2014-05 Impact factor: 4.129